Efficacy and safety of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3G or primary IC-MPGN: 12-week results from the NOBLE study (Southwest Nephrology 2024 C3G) - Apellis Medical Hub

Efficacy and safety of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3G or primary IC-MPGN: 12-week results from the NOBLE study

Share Via Email

Back to Conference Resources

IC-MPGN and C3G Congress Presentations Southwest Nephrology 2024

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.